Beyond the Whey: Verley’s Strategic Pivot to Precision-Fermented BLG at Scale

As the global food-tech sector matures, the era of "lab-to-table" enthusiasm is being replaced by the era of "prove-it" industrialization. French precision fermentation startup Verley is at the vanguard of this shift, moving aggressively from laboratory R&D to commercial-scale manufacturing. With a focus on the high-value dairy protein beta-lactoglobulin (BLG), Verley is currently scaling production to 200,000-liter fermentation tanks, positioning itself not as a commodity rival to conventional whey, but as a specialized provider of next-generation functional ingredients.

The Core Mission: Unlocking the Power of BLG

At the heart of Verley’s business model is a departure from the "me-too" approach. Many alternative protein companies have attempted to recreate the entire milk profile, often struggling with cost structures and consumer acceptance. Verley has taken a more surgical approach: isolating and producing beta-lactoglobulin (BLG) through precision fermentation.

BLG is a major component of whey protein, highly valued for its nutritional profile and its role in muscle protein synthesis. By using microbes to "brew" this specific protein, Verley achieves a level of purity that conventional dairy processing—which relies on the separation of complex whey mixtures—simply cannot replicate.

"We are not just whey," explains Stéphan Mac Millan, co-founder and CEO of Verley. "We are BLG. The purity level is super high, which allows us to achieve functionality that the conventional industry struggles to match."

Chronology of Progress: From Lab to Industrial Reality

Verley’s journey has been marked by a disciplined, milestone-driven strategy.

• Foundation and R&D: The company spent its initial years perfecting the fermentation process, focusing on microbial efficiency and the proprietary "micro-particulation" technology that gives their BLG its unique functional stability.
• Regulatory Milestones: A critical turning point occurred in September 2025, when the company secured a "no questions" letter from the US Food and Drug Administration (FDA) regarding its GRAS (Generally Recognized as Safe) status. This served as the green light for the North American market.
• Funding Injection: Early in 2026, the company successfully closed a €32 million ($36 million) Series A round, providing the runway necessary to transition from pilot-scale production to industrial-scale manufacturing.
• Current Phase: The company is currently finalizing its move into 200,000-liter fermentation tanks at a third-party co-manufacturer. This scale is intended to support the transition to full commercial sales scheduled for 2027.
• Future Outlook: Following the North American launch, Verley is targeting the GCC region and Canada, with a longer-term roadmap for entry into the Asian markets and a multi-year effort to secure novel food approval in the European Union.

Supporting Data: Functionality as a Competitive Edge

The market for functional protein is shifting toward convenience and performance. Verley’s internal data highlights two primary applications where their BLG outperforms traditional proteins:

1. High-Density Protein Shots: Conventional whey proteins often become viscous or unstable when concentrated. Verley has successfully demonstrated the ability to pack 25 grams of protein into a 100-ml shot, maintaining low viscosity, high solubility, and clarity. This is a critical selling point for the sports nutrition and medical nutrition markets, where consumers seek high protein intake with minimal volume.
2. Ultra-High-Protein Yogurts: Traditional UHT drinkable yogurts hit a "texture wall" at approximately 9% protein, after which the product becomes sandy and unpalatable. Verley’s micro-particulated BLG has pushed this threshold to 13%, allowing for a "protein-boosted" yogurt that retains the creamy mouthfeel consumers expect.

These are not merely theoretical advantages; the company reports over 20 active applications in development within the food and beverage industry.

Official Perspectives: The "Prove-It" Phase of Foodtech

In a recent interview at the Future Food-Tech summit in London, CEO Stéphane Mac Millan addressed the shifting sentiment in the investment community. He emphasized that the "exuberance" of 2020–2022 has vanished, replaced by a cold, hard focus on operational viability.

On Production and DSP (Downstream Processing)

When asked about the most challenging aspect of scale, Mac Millan steered the conversation away from basic fermentation yields. "On titer, yield, and productivity, we are where we want to be," he noted. The real bottleneck, according to Mac Millan, is downstream processing (DSP)—the purification phase. Every purification step introduces the risk of yield loss. Verley’s current engineering focus is on maximizing recovery efficiency to ensure that nearly 100% of the protein produced in the tank makes it into the final product.

On Price Parity and Competition

One of the most persistent criticisms of precision fermentation is the high cost compared to commodity dairy. Mac Millan argues that Verley is not competing with commodity prices. "We are already at price parity with Arla’s extracted BLG, which is north of $40 per kg," he explains. He asserts that the value proposition of Verley’s BLG lies in the performance it enables, not the baseline cost per gram. The focus is on the "value-add"—the ability to create products that were previously impossible to manufacture.

On Scaling and Infrastructure

Mac Millan offered a candid assessment of the "build vs. buy" debate regarding manufacturing facilities. While he acknowledges that owning facilities is the eventual goal for any major player, he warns against using venture capital for asset-heavy infrastructure. "You don’t finance a $200 million facility with VC money," he says. "VC is for risk. You build your own plants only when the technology is proven, the market is locked in, and your offtakes are secured for the next four years. Doing it any earlier is a recipe for disaster."

Implications for the Broader Market

Verley’s trajectory signals several significant shifts in the food-tech landscape:

The Professionalization of Ingredients

The industry is moving away from the "novelty" phase. Companies are now looking at protein ingredients with the same technical rigor as pharmaceutical companies. The fact that major players like Hilmar Ingredients are already highlighting BLG content in their marketing suggests that the ingredient is gaining institutional legitimacy.

A Data-Driven Regulatory Pathway

By prioritizing the US "no questions" GRAS status, Verley has demonstrated that regional regulatory strategy is just as important as R&D. The company’s patience regarding the European Union—a notoriously difficult regulatory environment—shows a sophisticated understanding of global market entry.

Shift in Investor Expectations

Verley’s success in securing its Series A round during a "down" market for food-tech suggests that investors are once again writing checks, but only for companies that can demonstrate:

1. Validated Market Demand: Customers must be asking for the product, not just the startup pitching it.
2. Sample-Based Proof: The technology must be in the hands of potential clients for testing.
3. Scalability: A clear, documented path to industrial-scale, repeatable quality.

Conclusion

Verley is currently navigating the most difficult phase for any deep-tech startup: the transition from a successful pilot to a reliable commercial supplier. By focusing on the high-performance niche of BLG, they have successfully carved out a value proposition that sidesteps the "commodity trap" of basic whey. If the company successfully hits its 2027 commercialization targets, it will provide a blueprint for how precision fermentation firms can survive and thrive in a more skeptical, performance-oriented investment climate. The success of the next eighteen months will determine whether Verley remains a promising biotech firm or becomes a foundational pillar in the future of the global dairy ingredients market.